Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Intellia Therapeutics (NTLA) Shares Outstanding (2016 - 2026)

Intellia Therapeutics has reported Shares Outstanding over the past 12 years, most recently at $120.4 million for Q1 2026.

  • Quarterly Shares Outstanding rose 16.33% to $120.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $120.4 million through Mar 2026, up 16.33% year-over-year, with the annual reading at $116.3 million for FY2025, 14.0% up from the prior year.
  • Shares Outstanding was $120.4 million for Q1 2026 at Intellia Therapeutics, up from $116.3 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $120.4 million in Q1 2026 and troughed at $87751.0 in Q3 2024.
  • The 5-year median for Shares Outstanding is $89.1 million (2023), against an average of $84.7 million.
  • Year-over-year, Shares Outstanding plummeted 99.97% in 2022 and then surged 366316.44% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $87.1 million in 2022, then increased by 6.77% to $93.0 million in 2023, then increased by 9.71% to $102.0 million in 2024, then grew by 14.0% to $116.3 million in 2025, then rose by 3.55% to $120.4 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Shares Outstanding are $120.4 million (Q1 2026), $116.3 million (Q4 2025), and $115.8 million (Q3 2025).